Back

Baseline cardiovascular risk in subjects with type 2 diabetes and chronic kidney disease from the FLOW trial

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Renal failure and cardiovascular disease 2 Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Kenneth W Mahaffey

Stanford University Medical Center, Stanford (United States of America)

5 More presentations in this session

Presentation thumbnail
Effects of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan: results from the phase 2 RESCUE-2 trial
Ms A. Pettersson Meyer (DK)
Abstract Slides
Presentation thumbnail
CAD in kidney transplant recipients: a real-world assessment pre-ISCHEMIA-CKD
Doctor B. Rocha (Lisbon, PT)
Abstract Slides
Presentation thumbnail
Epigenetic regulation of miR-181c-5p in a cardiorenal mouse model with co-occurring thrombotic microangiopathy
Ms J. Boen (Antwerp, BE)
Abstract Slides
Presentation thumbnail
Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial
Doctor A. Singh (Boston, US)
Abstract Slides
Presentation thumbnail
The difference in prognostic value between high-sensitive cardiac troponin T and I for long-term major adverse cardiovascular events in hemodialysis patients
Associate Professor W. Wongcharoen (Chiang Mai, TH)
Abstract Slides

Access the full session

Session thumbnail
Renal failure and cardiovascular disease 2

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources